KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) Return on Equity (2020 - 2024)

AbCellera Biologics' Return on Equity history spans 5 years, with the latest figure at 0.04% for Q3 2024.

  • For the quarter ending Q3 2024, Return on Equity rose 7.0% year-over-year to 0.04%, compared with a TTM value of 0.04% through Sep 2024, up 7.0%, and an annual FY2024 reading of 0.15%, down 2.0% over the prior year.
  • Return on Equity for Q3 2024 was 0.04% at AbCellera Biologics, up from 0.07% in the prior quarter.
  • The five-year high for Return on Equity was 0.35% in Q4 2020, with the low at 0.13% in Q4 2023.
  • Average Return on Equity over 5 years is 0.09%, with a median of 0.14% recorded in 2021.
  • Year-over-year, Return on Equity tumbled -31bps in 2023 and then grew 7bps in 2024.
  • Tracing ABCL's Return on Equity over 5 years: stood at 0.35% in 2020, then crashed by -56bps to 0.16% in 2021, then decreased by -18bps to 0.13% in 2022, then crashed by -198bps to 0.13% in 2023, then surged by 66bps to 0.04% in 2024.
  • Per Business Quant, the three most recent readings for ABCL's Return on Equity are 0.04% (Q3 2024), 0.07% (Q2 2024), and 0.09% (Q1 2024).